Full history for every metric is available with a Kvantra account
Labomar S.p.A. (LBM.MI)
Key financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | €m | 42 | 43 | 57 | 61 | 65 | 92 |
| Operating profit | €m | 9 | |||||
| Net profit | €m | 4 | 4 | 5 | 6 | 8 | 6 |
| EPS reported | € | 0.33 | |||||
| Operating cashflow per share | € | 0.54 | |||||
| Capex per share | € | 0.35 | |||||
| FCF per share | € | 0.19 | |||||
| Free cash flow | €m | 4 | |||||
| Net debt | €m | 20 | |||||
| Book value equity | €m | 51 | |||||
| Book value per share | € | 2.76 | |||||
| Number of shares | m | 18.48 | |||||
| DPS (TTM paid) | € | 0.10 |
Financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | 27.21 | |||||
| P/B LTM | x | 3.25 | |||||
| P/S LTM | x | 1.81 | |||||
| P/FCF LTM | x | 46.32 | |||||
| EV/EBITDA LTM | x | 11.47 | |||||
| EV/Sales LTM | x | 2.03 | |||||
| Earnings Yield LTM | % | 3.68% | |||||
| FCF Yield | % | 2.16% | |||||
| Quality | |||||||
| ROE | % | 12.05% | |||||
| ROIC | % | 6.15% | |||||
| Operating margin | % | 10.29% | |||||
| Gross margin | % | 37.91% | |||||
| FCF/Sales | % | 3.90% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | -26.67% | |||||
| Sales Growth YoY | % | +40.38% | |||||
| Net Income Growth YoY | % | -26.51% | |||||
| FCF Growth | % | -33.76% | |||||
| Operating Profit Growth | % | +71.21% | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 1.11% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 30.08% | |||||
| FCF/Debt | x | 0.09 | |||||
| Net Debt/EBITDA | x | 1.25 | |||||
| EBIT/Net interest | x | 13.46 | |||||
| Net debt/market cap | % | 12.22% | |||||
| Net debt/Equity | x | 0.40 | |||||
| Gross debt/equity | x | 0.81 | |||||
Company overview
Labomar S.p.A., an Italian company established in 1998 and headquartered in Istrana, specializes in the global research, development, production, and commercialization of a wide range of health-focused products. Its market presence spans Italy, France, Poland, Spain, North America, and other international regions. The company's comprehensive product line includes food supplements addressing diverse therapeutic needs such as immune system support, digestive health, respiratory conditions (cough and cold), neurological wellness, oncology support, vision care, sports nutrition, dermatological health, 'inside beauty' applications, cardiovascular health, orthopedic issues, pediatrics, detoxification, and metabolic syndrome management. This segment also features essential vitamins, minerals, and antioxidants. Labomar further manufactures medical devices for use in gynecology, respiratory and gastrointestinal ailments, wound healing, metabolic disorders, proctology, detoxification, and oral wound care. Additionally, it provides foods for special medical purposes, catering to needs in gastroenterology, endocrinology, and dysphagia. Within its cosmetics division, the company develops products for internal beauty, skin cleansing, general skincare, haircare, oral wound care, sun protection, and specific dermatological conditions including acne rosacea, acne, atopic dermatitis, and bruises. Probiotic food supplements are also part of its offerings. Beyond its proprietary brands, Labomar extends its expertise through contract development and manufacturing services for other companies. Its products are available in various formats, including tablets, capsules, liquids, powders, and semi-solids. A significant commercial partnership with Bayer involves Labomar in the development and production of various pharmaceutical formulations in different flavors and forms.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Labomar S.p.A. (LBM.MI)
Labomar S.p.A., an Italian company established in 1998 and headquartered in Istrana, specializes in the global research, development, production, and commercialization of a wide range of health-focused products. Its market presence spans Italy, France, Poland, Spain, North America, and other international regions. The company's comprehensive product line includes food supplements addressing diverse therapeutic needs such as immune system support, digestive health, respiratory conditions (cough and cold), neurological wellness, oncology support, vision care, sports nutrition, dermatological health, 'inside beauty' applications, cardiovascular health, orthopedic issues, pediatrics, detoxification, and metabolic syndrome management. This segment also features essential vitamins, minerals, and antioxidants. Labomar further manufactures medical devices for use in gynecology, respiratory and gastrointestinal ailments, wound healing, metabolic disorders, proctology, detoxification, and oral wound care. Additionally, it provides foods for special medical purposes, catering to needs in gastroenterology, endocrinology, and dysphagia. Within its cosmetics division, the company develops products for internal beauty, skin cleansing, general skincare, haircare, oral wound care, sun protection, and specific dermatological conditions including acne rosacea, acne, atopic dermatitis, and bruises. Probiotic food supplements are also part of its offerings. Beyond its proprietary brands, Labomar extends its expertise through contract development and manufacturing services for other companies. Its products are available in various formats, including tablets, capsules, liquids, powders, and semi-solids. A significant commercial partnership with Bayer involves Labomar in the development and production of various pharmaceutical formulations in different flavors and forms.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free